false 0001000694 0001000694 2024-05-10 2024-05-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549











Date of Report (Date of earliest event reported): May 10, 2024




(Exact name of registrant as specified in charter)  



Delaware   0-26770   22-2816046

(State or Other Jurisdiction

of Incorporation)

  (Commission File Number)  

(I.R.S. Employer

Identification No.)


700 Quince Orchard Road

Gaithersburg, Maryland 20878

(Address of Principal Executive Offices, including Zip Code)


(240) 268-2000

(Registrant’s telephone number, including area code)


(Former name or former address, if changed since last report.)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading
  Name of each exchange on which
Common Stock, Par Value $0.01 per share   NVAX   The Nasdaq Global Select Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨






Item 2.02. Results of Operations and Financial Condition.


Fourth Quarter Financial Results


On May 10, 2024, Novavax, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2024. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits.


99.1   Press release, dated May 10, 2024, regarding the Company’s financial results for the quarter ended March 31, 2024.
104   Cover Page Interactive Data File (formatted as Inline XBRL).







Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  Novavax, Inc.
Date: May 10, 2024 By: /s/ Mark J. Casey
  Name: Mark J. Casey
  Title: Executive Vice President, Chief Legal Officer and Corporate Secretary



EX-99.1 2 tm2414089d2_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1


Press Release 


Novavax Reports First Quarter 2024 Financial Results and Operational Highlights


·Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax’s Matrix-MTM adjuvant
·This agreement represents a potential multi-billion dollar revenue opportunity for Novavax including:
o$500 million upfront payment
oApproximately $70 million equity investment in Novavax
oUp to $700 million in COVID-19 and combination product near-term milestones, plus ongoing tiered royalties on product sales
oUp to $200 million in milestones plus royalties for each new vaccine developed utilizing Novavax’s Matrix-MTM adjuvant
·Announces addition of standalone influenza vaccine to Phase 3 COVID-19-Influenza Combination vaccine trial, which is on-track to initiate second half of 2024, with potential 2026 launch for both candidates
·Reduced current liabilities by an additional $831 million during Q1 2024
·Achieved total revenue in Q1 2024 of $94 million
·Novavax removes going concern notice
·Company to host conference call today at 8:30 a.m. ET


GAITHERSBURG, Md., May 10, 2024 – Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced its financial results and operational highlights for the first quarter ended March 31, 2024.


Earlier today, Novavax and Sanofi (NASDAQ: SNY) announced that they have entered into a co-exclusive licensing agreement. The terms of the agreement include: a co-exclusive license to co-commercialize Novavax’s current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements [APAs] and in India, Japan and South Korea where Novavax has existing partnership agreements); a sole license to Novavax’s adjuvanted COVID-19 vaccine for use in combination with Sanofi’s flu vaccines while Novavax retains the right to and is developing its own COVID-19-Influenza Combination (CIC) vaccine candidate; a non-exclusive license to use Novavax’s adjuvanted COVID-19 vaccine for use in combination with non-flu vaccines; and a non-exclusive license to use the Matrix-M adjuvant in vaccine products. In addition, Sanofi will take a minority (<5%) equity investment in Novavax.


“Today we announce the beginning of an exciting new chapter for Novavax with the launch of a strategically important partnership with one of the world’s leading vaccine companies. We believe the combined strength of Novavax and Sanofi will enable us to better fulfill our mission of developing and improving access to life-saving vaccines,” said John C. Jacobs, President and Chief Executive Officer, Novavax. “I am proud of the progress our Company has made this quarter as we continue to advance our COVID-19 vaccine for the upcoming 2024-2025 vaccination season and plan for the launch of our Phase 3 CIC and standalone influenza program in the second half of this year.”





The agreement is further validation of Novavax’s technology platform and provides significant opportunity to drive value creation and benefit global public health. It strengthens Novavax’s balance sheet and cash flow position, providing the opportunity to focus more on research and development and pipeline expansion to accelerate growth and generate long-term value for shareholders.


Sanofi Agreement Highlights


Financial Highlights


·This agreement represents a potential multi-billion dollar revenue opportunity for Novavax.


·The total value of near-term upfront payments, Sanofi’s equity investment and potential milestones associated with Nuvaxovid™ sales and the development of Sanofi’s flu-COVID-19 combination vaccine equate to approximately $1.3 billion.
oNovavax will receive an upfront payment of $500 million within 10 days.
oNovavax will receive today an equity investment of approximately $70 million in Novavax common stock for a 4.9% minority interest.
oNovavax is eligible to receive up to $350 million in milestones for activities related to Nuvaxovid.
oNovavax is eligible to receive up to $350 million in additional milestones for Sanofi’s flu-COVID-19 combination vaccine.


·In addition, Novavax is eligible to receive royalties associated with the ongoing sales of Nuvaxovid and Sanofi’s flu-COVID-19 combination vaccine and any other combination vaccines Sanofi may develop including Nuvaxovid.


·And finally, for each additional Sanofi vaccine product developed under the non-exclusive license with Novavax’s Matrix-M adjuvant technology, Novavax is eligible to receive additional launch and sales milestones of up to $200 million per product plus ongoing product royalties.


Additional Highlights


·Novavax is eligible for cost reimbursement by Sanofi of certain R&D and medical affairs costs, select technology transfer costs and supply of COVID-19 and Matrix-M adjuvant.


·Sanofi will be solely responsible for the development and commercialization of any novel flu-COVID-19 combination product containing a Sanofi flu vaccine, and any other combination products they may develop utilizing Nuvaxovid and any other new vaccines they develop utilizing the Matrix-M adjuvant.





·Outside of the collaboration, each party may develop and commercialize their own COVID-19-Influenza combination vaccines and adjuvanted products at their own cost.


First Quarter 2024 and Recent Highlights


During the first quarter, Novavax continued executing against its three key priorities for 2024.


Priority #1: Deliver an Updated COVID-19 Vaccine for the 2024-2025 Vaccination Season


U.S. Market:


·Updated protein-based COVID-19 vaccine to JN.1 with anticipated pre-filled syringe presentation.


·Completed the submission of the Biologics License Application for Novavax's COVID-19 vaccine with the U.S. Food and Drug Administration (FDA).


·Aligned with the FDA on pathway for Emergency Use Authorization for updated COVID-19 vaccine for the 2024-2025 vaccination season, with the intent of facilitating product availability at the beginning of the season.


·Advanced retail pharmacy contract negotiations for the 2024-2025 vaccination season.


Global Markets:


·Delivered doses of Nuvaxovid XBB.1.5 vaccine to Europe and for distribution by the Taiwan Centers for Disease Control.


·Received marketing authorization from the United Kingdom’s (U.K.) Medicines and Healthcare products Regulatory Agency for Nuvaxovid XBB.1.5 in individuals aged 12 and older in January and progressed preparations for participation in the U.K. spring campaign for private healthcare providers.


·Granted full approval from Singapore’s Health Sciences Authority for Nuvaxovid XBB.1.5 for active immunization to prevent COVID-19 in individuals aged 12 and older.


Priority #2: Launch Phase 3 trial of CIC and Stand-alone Influenza Program


Novavax remained focused on leveraging its technology platform, including its proprietary Matrix-M adjuvant, to expand its pipeline with CIC and stand-alone influenza vaccine candidates.


·Made strategic decision to add a stand-alone influenza arm to the Phase 3 trial and to focus on individuals at higher risk by enrolling adults aged 60 and older for both the stand-alone influenza and CIC arms of the trial.





·On track to submit an investigational new drug application and initiate the pivotal Phase 3 trial for both CIC and stand-alone influenza vaccine candidates in the second half of 2024, with potential for accelerated approval and launch in 2026.


·Continued to optimize preclinical candidates, including a new approach to H5N1 pandemic bird flu vaccination, and expanded core technology for novel applications including mucosal vaccination and high-density nanoparticles.


Priority #3: Continue Evolution of Novavax, Further Reducing Operating Expenses


Novavax has made significant progress on its commitment to improve its financial position while maintaining the capabilities that support long-term value creation.


·On track with global restructuring and cost reduction plan, continued to transform the Company into a more lean and agile organization, with an approximately 50% reduction in combined R&D and SG&A expenses in the first quarter of 2024 compared to 2023.


·Since December 31, 2022, reduced current liabilities by $1.7 billion, including an additional $831 million reduction in the first quarter of 2024, primarily driven by the settlements with Gavi, the Vaccine Alliance and Fujifilm Diosynth Biotechnologies.


First Quarter 2024 Financial Results


·Total revenue for the first quarter of 2024 was $94 million, compared to $81 million in the same period in 2023.


·Cost of sales for the first quarter of 2024 was $59 million, compared to $34 million in the same period in 2023. These quarters included $15 million and $25 million, respectively, related to excess, obsolete or expired inventory, losses on firm purchase commitments under third-party supply agreements and unutilized manufacturing capacity.


·R&D expenses for the first quarter of 2024 were $93 million, compared to $247 million in the same period in 2023. The decrease was primarily due to reductions in manufacturing and clinical research-related spend as well as a $27 million benefit associated with the favorable settlement of manufacturing liabilities recorded in the first quarter of 2024.





·SG&A expenses for the first quarter of 2024 were $87 million, compared to $113 million for the same period in 2023. The decrease was primarily due to the Company's continued cost containment measures to reduce operating spend.


·Net loss for the first quarter 2024 was $148 million, compared to a net loss of $294 million in the same period in 2023.


·Cash, cash equivalents and restricted cash were $496 million as of March 31, 2023, compared to $584 million as of December 31, 2023.


Financial Framework


Novavax is updating its Full Year 2024 Financial Guidance and expects to achieve the following objectives:


Full Year 2024 Guidance


$ in millions Prior
(as of February 28, 2024)
(as of May 10, 2024)
Combined Revenue and Sanofi Agreement Payments $800 - $1,000 $970 - $1,170
Total Revenue1,2 $800 - $1,000 $400 - $600
Initial Sanofi Agreement Payments3   ~$570
Combined R&D and SG&A $700 - $800 $700 - $750


1.Total Revenue includes product sales and royalties and other revenue.
2.Full year 2024 guidance reflects APA expected dose delivery schedules of $150 million to $250 million and non-APA related revenue of $250 million to $350 million, subject to updated variant manufacturing and regulatory approvals, from a combination of commercial market product sales plus royalties and other revenue from partner-related activity. The update to the expected 2024 APA dose delivery schedules reflects the anticipated shift of approximately $250 million in contracted doses from 2024 to future periods.
3.Sanofi agreement initial payments include a non-refundable $500 million upfront payment to be received within 10 days and an immediate $69 million equity investment in Novavax.


Total potential contract value for APAs outstanding, as of March 31, 2024, was over $600 million related to expected dose deliveries for the second quarter of 2024 through 2026. This amount excludes deferred revenue associated with the 2023 Canada amendments to forfeit doses.


Novavax is prepared to initiate an additional cost reduction program to reduce 2025 R&D plus SG&A expenses to below $500 million, a portion of which it expects to be reimbursed by Sanofi under the agreement. This reflects a greater than $225 million reduction beyond prior stated targets.


Intends to further reshape the size and scope of global business operations to prioritize enabling Sanofi to successfully execute its commercial and development plans under the agreement, deliver on existing Novavax APAs and focus on creating value from R&D and business development.





Conference Call


Novavax will host its quarterly conference call today at 8:30 a.m. ET. To join the call without operator assistance, you may register and enter your phone number at https://emportal.ink/3VNP8J5 to receive an instant automated call back. You may also dial direct to be entered to the call by an operator. The dial-in numbers for the conference call are (888) 664-6383 (Domestic) or (+1) (416) 764-8650 (International). Participants will be prompted to request to join the Novavax, Inc. call. A replay of the conference call will be available starting at 11:30 a.m. EST on May 10, 2024, until 11:59 p.m. ET on May 17, 2024. To access the replay by telephone, dial (888) 390-0541 (Domestic) or (+1) (416) 764-8677 (International) and use passcode 414036 #.


A webcast of the conference call can also be accessed on the Novavax website at ir.novavax.com/events. A replay of the webcast will be available on the Novavax website until June 10, 2024.


Trade Name in the U.S.


The trade name Nuvaxovid™ has not been approved by the U.S. FDA.


About Novavax


Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company’s portfolio includes its COVID-19 vaccine and its pipeline includes CIC and stand-alone influence vaccine candidates. In addition, Novavax’s adjuvant is included in the University of Oxford and Serum Institute of India’s R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.





Forward-Looking Statements


Statements herein relating to the future of Novavax, its mission, its near-term priorities including delivering an updated COVID-19 vaccine for the start of the 2024-2025 vaccination season in a pre-filled syringe presentation, launching a Phase 3 trial for CIC and stand-alone influenza in the second half of 2024, with possible combination vaccine and stand-alone influenza vaccine launch in 2026, and reducing operations expenses, including by initiating an additional cost reduction program, the anticipated timing of potential BLA approval for Novavax’s prototype vaccine and EUA for Novavax’s updated COVID-19 vaccine, potential royalties and milestones under the agreement with Sanofi, its operating plans, objectives and prospects, updated full year 2024 financial guidance, its future financial or business performance, conditions or strategies, and its ability to attain contract value under existing APAs are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, Novavax’s and Sanofi’s ability to successfully implement its partnership, including the ability to transition key processes and effect technology transfers, Novavax’s ability to successfully and timely manufacture, distribute, or market its updated COVID-19 vaccine including as a single dose vial or pre-filled syringe product presentation for the 2024-2025 vaccination season; challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification, assay validation and stability testing, necessary to satisfy applicable regulatory authorities; challenges or delays in conducting clinical trials; challenges or delays in obtaining regulatory authorization for its product candidates, including its updated COVID-19 vaccine in time for the 2024-2025 vaccination season or for future COVID-19 variant strain changes, its CIC and stand-alone influenza vaccine candidate; manufacturing, distribution or export delays or challenges; Novavax's substantial dependence on Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for co-formulation and filling and PCI Pharma Services for finishing Novavax’s COVID-19 vaccine and the impact of any delays or disruptions in their operations on the delivery of customer orders; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, constraints on Novavax’s ability to pursue planned regulatory pathways, alone or with partners, in multiple jurisdictions simultaneously, leading to staggering of regulatory filings, and potential regulatory actions; challenges in implementing its global restructuring and cost reduction plan; Novavax’s ability to timely deliver doses; challenges in obtaining commercial adoption and market acceptance of its updated COVID-19 vaccine or any COVID-19 variant strain containing formulation; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities, including requirements to deliver doses that may require Novavax to refund portions of upfront and other payments previously received or result in reduced future payments pursuant to such agreements; challenges related to the seasonality of vaccinations against COVID-19; and those other risk factors identified in the “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.








   Three Months Ended
March 31,
   2024   2023 
Product sales  $82,324   $(7,457)
Grants   --    87,379 
Royalties and other   11,531    1,029 
Total revenue   93,855    80,951 
Cost of sales   59,209    34,086 
Research and development   92,679    247,101 
Selling, general and administrative   86,798    112,532 
Total expenses   238,686    393,719 
Loss from operations   (144,831)   (312,768)
Interest expense   (4,111)   (4,316)
Other income   3,654    24,362 
Loss before income taxes   (145,288)   (292,722)
Income tax expense   2,262    1,183 
Net loss  $(147,550)  $(293,905)
Net loss per share Basic and Diluted  $(1.05)  $(3.41)
Weighted average number of common shares outstanding Basic and Diluted   139,916    86,158 






(in thousands)


   March 31,
   December 31,
Cash and cash equivalents  $480,586   $568,505 
Total restricted cash   15,350    15,305 
Total current assets   727,120    1,143,888 
Working capital    (77,262)   (491,250)
Total assets   1,353,534    1,794,490 
Convertible notes payable   168,432    168,016 
Total stockholders’ deficit   (867,084)   (716,927)





Erika Schultz





Giovanna Chandler






EX-101.SCH 3 nvax-20240510.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 nvax-20240510_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 nvax-20240510_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2414089d2_ex99-1img001.jpg GRAPHIC begin 644 tm2414089d2_ex99-1img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
May 10, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 10, 2024
Entity File Number 0-26770
Entity Registrant Name NOVAVAX, INC.
Entity Central Index Key 0001000694
Entity Tax Identification Number 22-2816046
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 700 Quince Orchard Road
Entity Address, City or Town Gaithersburg
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20878
City Area Code 240
Local Phone Number 268-2000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.01 per share
Trading Symbol NVAX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://novavax.com/role/Cover Cover Cover 1 false false All Reports Book All Reports nvax-20240510.xsd nvax-20240510_lab.xml nvax-20240510_pre.xml tm2414089d2_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2414089d2_8k.htm": { "nsprefix": "nvax", "nsuri": "http://novavax.com/20240510", "dts": { "schema": { "local": [ "nvax-20240510.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "nvax-20240510_lab.xml" ] }, "presentationLink": { "local": [ "nvax-20240510_pre.xml" ] }, "inline": { "local": [ "tm2414089d2_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://novavax.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-10", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2414089d2_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-10", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2414089d2_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://novavax.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-059659-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-059659-xbrl.zip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end XML 18 tm2414089d2_8k_htm.xml IDEA: XBRL DOCUMENT 0001000694 2024-05-10 2024-05-10 iso4217:USD shares iso4217:USD shares false 0001000694 8-K 2024-05-10 NOVAVAX, INC. DE 0-26770 22-2816046 700 Quince Orchard Road Gaithersburg MD 20878 240 268-2000 false false false false Common Stock, Par Value $0.01 per share NVAX NASDAQ false